Checkpoint inhibitors and myeloma: promises, deadlocks and new directions.
作者信息
Bertamini Luca, Gay Francesca
机构信息
Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
出版信息
Ann Transl Med. 2020 Jun;8(12):777. doi: 10.21037/atm.2020.02.65.
Abstract
摘要
相似文献
1
Checkpoint inhibitors and myeloma: promises, deadlocks and new directions.检查点抑制剂与骨髓瘤：前景、僵局与新方向
Ann Transl Med. 2020 Jun;8(12):777. doi: 10.21037/atm.2020.02.65.
2
The challenges of checkpoint inhibition in the treatment of multiple myeloma.在多发性骨髓瘤治疗中抑制检查点所面临的挑战。
Cell Immunol. 2018 Dec;334:87-98. doi: 10.1016/j.cellimm.2018.10.003. Epub 2018 Oct 13.
3
Checkpoint inhibition in myeloma.骨髓瘤中的检查点抑制
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):528-533. doi: 10.1182/asheducation-2016.1.528.
4
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.免疫肿瘤学方法：嵌合抗原受体T细胞（CAR-T细胞）与免疫检查点抑制剂
Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):471-478. doi: 10.1016/j.clml.2017.06.014. Epub 2017 Jun 17.
5
Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.淋巴瘤和骨髓瘤的免疫治疗：现状与展望。
Clin Cancer Res. 2018 Mar 1;24(5):1002-1010. doi: 10.1158/1078-0432.CCR-17-0539. Epub 2017 Sep 12.
6
Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.免疫疗法在靶向多发性骨髓瘤骨髓微环境中的作用：一种不断发展的治疗策略。
Pharmacotherapy. 2017 Jan;37(1):129-143. doi: 10.1002/phar.1871. Epub 2017 Jan 6.
7
Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.多发性骨髓瘤中单克隆抗体和检查点阻断治疗的临床和药理学特征。
Curr Med Chem. 2019;26(32):5968-5981. doi: 10.2174/0929867325666180514114806.
8
Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges.检查点抑制剂与急性髓系白血病：前景与挑战
Expert Rev Hematol. 2018 May;11(5):373-389. doi: 10.1080/17474086.2018.1459184.
9
Cellular immunotherapy as a therapeutic approach in multiple myeloma.细胞免疫疗法作为多发性骨髓瘤的一种治疗方法。
Expert Rev Hematol. 2018 Jul;11(7):525-536. doi: 10.1080/17474086.2018.1483718.
10
How is patient care for multiple myeloma advancing?多发性骨髓瘤的患者护理是如何取得进展的？
Expert Rev Hematol. 2017 Jun;10(6):551-561. doi: 10.1080/17474086.2017.1326814. Epub 2017 May 19.
引用本文的文献
1
Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors.在骨髓瘤患者中，PD-1 和 CTLA-4 检查点的异常表达在诊断时更为明显：对进展时间和治疗性检查点抑制剂反应的影响。
Int J Mol Sci. 2023 Mar 17;24(6):5730. doi: 10.3390/ijms24065730.
2
Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next?治疗B细胞恶性肿瘤新型药物的现状：接下来会有什么进展？
Cancers (Basel). 2022 Dec 7;14(24):6026. doi: 10.3390/cancers14246026.
本文引用的文献
1
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.帕博利珠单抗联合来那度胺和地塞米松用于初治多发性骨髓瘤患者（KEYNOTE-185）：一项随机、开放标签的3期试验。
Lancet Haematol. 2019 Sep;6(9):e448-e458. doi: 10.1016/S2352-3026(19)30109-7. Epub 2019 Jul 18.
2
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.帕博利珠单抗联合泊马度胺和地塞米松治疗复发或难治性多发性骨髓瘤患者（KEYNOTE-183）：一项随机、开放标签的3期试验。
Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.
3
Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.帕博利珠单抗联合来那度胺及低剂量地塞米松治疗复发或难治性多发性骨髓瘤：I期KEYNOTE-023研究
Br J Haematol. 2019 Sep;186(5):e117-e121. doi: 10.1111/bjh.15946. Epub 2019 May 15.
4
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma.PD-1/PD-L1 抑制剂在多发性骨髓瘤中的应用的承诺和陷阱。
Front Immunol. 2018 Nov 27;9:2749. doi: 10.3389/fimmu.2018.02749. eCollection 2018.
5
Autoimmunity and primary immunodeficiency: two sides of the same coin?自身免疫与原发性免疫缺陷：同一枚硬币的两面？
Nat Rev Rheumatol. 2017 Dec 19;14(1):7-18. doi: 10.1038/nrrheum.2017.198.
6
Novel Immunotherapies for Multiple Myeloma.多发性骨髓瘤的新型免疫疗法
Curr Hematol Malig Rep. 2017 Aug;12(4):344-357. doi: 10.1007/s11899-017-0397-7.
7
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.免疫肿瘤学方法：嵌合抗原受体T细胞（CAR-T细胞）与免疫检查点抑制剂
Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):471-478. doi: 10.1016/j.clml.2017.06.014. Epub 2017 Jun 17.
8
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.帕博利珠单抗、泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤。
Blood. 2017 Sep 7;130(10):1189-1197. doi: 10.1182/blood-2017-03-775122. Epub 2017 May 1.
9
Autoimmunity and infection in common variable immunodeficiency (CVID).普通变异性免疫缺陷症（CVID）中的自身免疫和感染。
Autoimmun Rev. 2016 Sep;15(9):877-82. doi: 10.1016/j.autrev.2016.07.011. Epub 2016 Jul 6.
10
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.达雷妥尤单抗可清除CD38+免疫调节细胞，促进T细胞扩增，并使多发性骨髓瘤中的T细胞库发生偏移。
Blood. 2016 Jul 21;128(3):384-94. doi: 10.1182/blood-2015-12-687749. Epub 2016 May 24.
Zotero 插件